Abstract
BackgroundKeloid disease is hard to fully eradicate. Recurrence and other unsatisfactory results were found in many patients. No current therapeutic modality has been determined to be most effective for treating keloid scars. Intralesional corticosteroid injections is most commonly recommended for primary management of small and young keloids as well as hypertrophic scars. However, it’s difficult for patients to adhere to long-term triamcinolone acetonide injection therapy because of the pain, inconvenience or complications including hormonal imbalance or irregular menstruation.ObjectiveWe aimed to determine whether and how Strontium-90 brachytherapy as an adjuvant radiation could affect keloid recurrence after intralesional triamcinolone and 5-fluorouracil injections.MethodsWe included keloid patients from March 2019 to September 2019 and randomly allocated them to two groups after 3 intralesional triamcinolone and 5-fluorouracil injections at 3 weeks interval. The experimental group received Strontium-90 brachytherapy at a total dose of 15-20Gy, while the control group didn’t receive any adjuvant treatment. We performed both Vancouver Scar Scale scoring and Color Doppler ultrasound examination to monitor and evaluate lesions regularly. A one-year follow-up was completed for each patient.Results31 patients who had 42 keloids in total were recruited. We found intralesional triamcinolone and 5-fluorouracil injections could effectively reduce the thickness and modify the hardness of small and young keloids. Strontium-90 brachytherapy reduced the one-year recurrence rate from 85.7 percent to 44.4 percent after 3 intralesional triamcinolone and 5-fluorouracil injections. The lesions’ thickness or elasticity was not affected by Strontium-90 brachytherapy.ConclusionStrontium-90 brachytherapy as an adjuvant radiation could effectively reduce small sized keloids recurrence after intralesional triamcinolone and 5-fluorouracil injections. It worked by enhancing the lesions’ stability post-injection.Trial registrationThe clinical trial registration number: ChiCTR2000030141.Name of trial registry: Chinese Clinical Trial Registry (http://www.chictr.org.cn/)
Highlights
A keloid is an abnormal proliferation of scar tissue that forms at the site of cutaneous injury
We found intralesional triamcinolone and 5-fluorouracil injections could effectively reduce the thickness and modify the hardness of small and young keloids
Intralesional injection of steroids, verapamil and 5-fluorouracil (5-FU) usage, cryotherapy, laser therapy, radiation therapy and combination therapy are effective therapeutic approaches recommended for patients under different conditions [1]
Summary
A keloid is an abnormal proliferation of scar tissue that forms at the site of cutaneous injury. It grows beyond the original margins of the scar and rarely regresses [1]. Intralesional injection of steroids, verapamil and 5-fluorouracil (5-FU) usage, cryotherapy, laser therapy, radiation therapy and combination therapy are effective therapeutic approaches recommended for patients under different conditions [1]. No single therapeutic modality has been determined experimentally to be most effective for treating keloid scars. Keloid recurrence and other unsatisfactory results were found in feedbacks of many patients. Keloid disease is hard to fully eradicate. No current therapeutic modality has been determined to be most effective for treating keloid scars. It’s difficult for patients to adhere to long-term triamcinolone acetonide injection therapy because of the pain, inconvenience or complications including hormonal imbalance or irregular menstruation
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
